Vistin Pharma ASA (VISTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vistin Pharma ASA (VISTN) has a cash flow conversion efficiency ratio of 0.022x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr6.37 Million ≈ $669.89K USD) by net assets (Nkr294.27 Million ≈ $30.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check VISTN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Vistin Pharma ASA - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Vistin Pharma ASA for net asset value and shareholders' equity analysis.
Vistin Pharma ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vistin Pharma ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Mulia Industrindo Tbk
JK:MLIA
|
-0.005x |
|
Taiwan Line Tek Electronic Co Ltd
TW:2462
|
0.027x |
|
Méliuz S.A
SA:CASH3
|
0.039x |
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TW:1762
|
-0.007x |
|
PT DFI Retail Nusantara Tbk
JK:HERO
|
0.026x |
|
Expensify Inc
NASDAQ:EXFY
|
0.001x |
|
SynAct Pharma AB
ST:SYNACT
|
-0.141x |
|
Bapcor Ltd
AU:BAP
|
0.032x |
Annual Cash Flow Conversion Efficiency for Vistin Pharma ASA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Vistin Pharma ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Vistin Pharma ASA (VISTN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr309.53 Million ≈ $32.57 Million |
Nkr107.86 Million ≈ $11.35 Million |
0.348x | +24.15% |
| 2023-12-31 | Nkr322.77 Million ≈ $33.96 Million |
Nkr90.59 Million ≈ $9.53 Million |
0.281x | +964.87% |
| 2022-12-31 | Nkr273.26 Million ≈ $28.76 Million |
Nkr-8.87 Million ≈ $-933.17K |
-0.032x | -165.44% |
| 2021-12-31 | Nkr275.89 Million ≈ $29.03 Million |
Nkr13.68 Million ≈ $1.44 Million |
0.050x | +109.27% |
| 2020-12-31 | Nkr272.40 Million ≈ $28.66 Million |
Nkr-145.73 Million ≈ $-15.34 Million |
-0.535x | -1267.99% |
| 2019-12-31 | Nkr413.40 Million ≈ $43.50 Million |
Nkr18.93 Million ≈ $1.99 Million |
0.046x | +140.47% |
| 2018-12-31 | Nkr348.85 Million ≈ $36.71 Million |
Nkr-39.48 Million ≈ $-4.15 Million |
-0.113x | -243.02% |
| 2017-12-31 | Nkr120.16 Million ≈ $12.64 Million |
Nkr9.51 Million ≈ $1.00 Million |
0.079x | -72.57% |
| 2016-12-31 | Nkr186.61 Million ≈ $19.64 Million |
Nkr53.84 Million ≈ $5.67 Million |
0.288x | -- |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.